Next Article in Journal
Current Strategies for Tracheal Replacement: A Review
Previous Article in Journal
Alantolactone Suppresses Proliferation and the Inflammatory Response in Human HaCaT Keratinocytes and Ameliorates Imiquimod-Induced Skin Lesions in a Psoriasis-Like Mouse Model
Article

Patient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results

1
Dermatology Department, University Hospital Miguel Servet, Aragon Psychodermatogy Research Group (GAI+PD), Paseo de Isabel la Catolica 1-3, 50009 Zaragoza, Spain
2
Psychology Department, University of Zaragoza, Aragon Psychodermatology Research Group (GAI+PD), c/Pedro Cerbuna 12, 50009 Zaragoza, Spain
3
Pharmacy Department, Royo Villanova Hospital, Avda. San Gregorio 30, 50015 Zaragoza, Spain
4
Health Sciences Faculty, San Jorge University, Zaragoza, Autovia Mudejar, Km 299, Villanueva de Gallego, 50830 Zaragoza, Spain
5
Pharmacoeconomics & Outcomes Research Iberia (PORIB), Paseo de Joaquín Rodrigo 4-I, Pozuelo de Alarcón, 28224 Madrid, Spain
6
Dermatology Department, Royo Villanova Hospital, Aragon Psychodermatology Research Group (GAI+PD), Avda. San Gregorio 30, 50015 Zaragoza, Spain
*
Author to whom correspondence should be addressed.
Academic Editor: Rolland Gyulai
Life 2021, 11(7), 617; https://doi.org/10.3390/life11070617
Received: 16 May 2021 / Revised: 21 June 2021 / Accepted: 23 June 2021 / Published: 25 June 2021
(This article belongs to the Topic Psychodermatology)
Dupilumab is used to treat atopic dermatitis (AD) patients who have proven to be refractory to previous treatments. The aim of this study was to assess evolution and patient reported outcome measures in adult patients with moderate-to-severe AD treated with dupilumab in routine clinical practice. The outcomes were evaluated and registered at baseline and weeks 16, 40 and 52. The variables evaluated were: disease severity, pruritus, stressful life events, difficulty to sleep, anxiety and depression, quality of life, satisfaction, adherence to the treatment, efficacy and safety. Eleven patients were recruited between 14 Nov 2017 and 16 Jan 2018. Demographic variables: 90% Caucasian, 82% women. Clinical variables: Mean duration of AD = 17.7 (±12.8), 91% had severe disease severity. At baseline, SCORAD median (range) score = 69.2 (34.8–89.2); itch was reported by 100% of patients; itch visual analogue scale median (range) was 9 (6–10); HADS median (range) total score = 13 (5–21); DLQI mean score = 16 (2–27); EQ-5D-3L median (range) = 57 (30–99). At week-52 there was a significant reduction of SCORAD scores median (range) = 4.3 (0–17.1), HADS total score median (range) = 2 (0–10) and improved quality of life EQ-5D-3L median (range) = 89 (92–60). This study confirms that dupilumab, used for 52-weeks under routine clinical practice, maintains the improved atopic dermatitis signs and symptoms obtained at week 16, with a good safety profile. View Full-Text
Keywords: atopic dermatitis; patient reported outcome measures; dupilumab; quality of life; satisfaction; efficacy; safety; adherence atopic dermatitis; patient reported outcome measures; dupilumab; quality of life; satisfaction; efficacy; safety; adherence
Show Figures

Figure 1

MDPI and ACS Style

Marron, S.E.; Tomas-Aragones, L.; Moncin-Torres, C.A.; Gomez-Barrera, M.; Aranibar, F.J.G.-L.d. Patient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results. Life 2021, 11, 617. https://doi.org/10.3390/life11070617

AMA Style

Marron SE, Tomas-Aragones L, Moncin-Torres CA, Gomez-Barrera M, Aranibar FJG-Ld. Patient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results. Life. 2021; 11(7):617. https://doi.org/10.3390/life11070617

Chicago/Turabian Style

Marron, Servando E., Lucia Tomas-Aragones, Carlos A. Moncin-Torres, Manuel Gomez-Barrera, and Francisco J.G.-L.d. Aranibar 2021. "Patient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results" Life 11, no. 7: 617. https://doi.org/10.3390/life11070617

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop